SCHEDULE 13G/A: FMR LLC and Abigail Johnson Reduce Passive Stake in Cellebrite DI Ltd. to 4.1%

FMR LLC and Abigail P. Johnson have disclosed a reduction in their passive beneficial ownership stake in Cellebrite DI Ltd. to 4.1% of common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, acting as reporting persons, jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Cellebrite DI Ltd. common stock.
• As of March 31, 2025, FMR LLC and Abigail P. Johnson collectively beneficially owned 9,925,217 shares of Cellebrite DI Ltd. common stock.
• This aggregate amount represents 4.1% of the total outstanding common stock of Cellebrite DI Ltd.
• FMR LLC holds sole voting and sole dispositive power over all 9,925,217 shares.
• Abigail P. Johnson holds sole dispositive power over the same 9,925,217 shares, with no sole or shared voting power.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cellebrite DI Ltd.
• The filing was made under Rule 13d-1(b), indicating a passive investment by an institutional investor.
• The Johnson family, including Abigail P. Johnson, are the predominant owners of FMR LLC, and may be deemed to form a controlling group with respect to FMR LLC.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the reduction in beneficial ownership by a major institutional investor, which implies a decreased level of confidence or a strategic divestment.

Positives

• The continued disclosure by a major institutional investor like FMR LLC indicates ongoing transparency regarding their holdings.
• The filing reaffirms that the investment is passive and not intended to influence control, which can provide stability to the company's governance structure.

Negatives

• The reduction of FMR LLC's beneficial ownership to 4.1% from a previous stake of 5% or more suggests a decrease in confidence or a reallocation of capital by a significant institutional investor.
• A decrease in institutional ownership can sometimes be perceived negatively by the market, potentially signaling a less favorable outlook for the company.

Risks

• The reduction in FMR LLC's stake could lead to negative market sentiment and potentially impact Cellebrite DI Ltd.'s share price.
• A decrease in institutional ownership might reduce the stock's liquidity or investor interest over time.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cellebrite DI Ltd.'s future financial performance or strategic outlook.

Industry Context

FMR LLC is one of the largest asset management firms globally, and its investment decisions are closely watched. Their reduction in stake in Cellebrite DI Ltd., a leader in digital intelligence solutions for public and private sectors, could reflect a broader re-evaluation of positions within the technology or cybersecurity sectors, or specific concerns related to Cellebrite's performance or valuation. This type of filing provides insight into institutional investor sentiment towards specific companies.

Stakeholder Impact

• Shareholders: May react negatively to the news of a significant institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• Investors: May interpret the reduction as a signal to re-evaluate their own positions in Cellebrite DI Ltd.

Key Dates

Recommendation

Keywords

Cellebrite DI Ltd, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, Institutional Investor, SEC Filing